Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal
Company Announcements

Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal

Poseida Therapeutics (PSTX) has shared an announcement.

Poseida Therapeutics, Inc. has forged a significant collaboration with Xyphos Biosciences, granting them exclusive licenses to utilize Poseida’s intellectual property in developing innovative CAR-T therapies for solid tumors. With an upfront payment of $50 million from Xyphos and potential for an additional $550 million in milestones, plus royalties on net sales, this agreement promises to propel cancer treatment research forward. However, the partnership carries risks, such as potential early termination and reliance on Xyphos for development progress, underscoring the uncertain yet hopeful journey towards new therapeutic discoveries.

See more insights into PSTX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyPoseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema
TheFlyPoseida Therapeutics nominates new CAR-T candidate under Roche collaboration
TheFlyPoseida Therapeutics reports data from Phase 1 trial of P-BCMA-ALLO1
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App